Acetazolamide

Acetazolamide

Usi approvati

• Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent.
• For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Forme e dosaggi

• Acetazolamide Tablets USP, 125 mg are available for oral administration as white to off white, round tablet, debossed HP 287 on one side and scored on other side.

Come si assume

• Glaucoma: Acetazolamide should be used as an adjunct to the usual therapy.
• The dosage employed in the treatment of chronic simple (open-angle) glaucoma ranges from 250 mg to 1 g of acetazolamide per 24 hours, usually in divided doses for amounts over 250 mg.
• It has usually been found that a dosage in excess of 1 g per 24 hours does not produce an increased effect.
• In all cases, the dosage should be adjusted with careful individual attention both to symptomatology and ocular tension.

Non deve essere usato in caso di

• Hypersensitivity to acetazolamide or any excipients in the formulation.
• Since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible.
• Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis.
• It is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy.

Avvertenze e precauzioni

• Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias, and anaphylaxis.
• Sensitizations may recur when a sulfonamide is readministered irrespective of the route of administration.
• If signs of hypersensitivity or other serious reactions occur, discontinue use of this drug.
• Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported.

Effetti indesiderati comuni

• Body as a whole: Headache, malaise, fatigue, fever, flushing, growth retardation in children, flaccid paralysis, anaphylaxis Digestive: Gastrointestinal disturbances such as nausea, vomiting, diarrhea Hematological/Lymphatic: Blood dyscrasias such as aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia, thrombocytopenic purpura, melena Hepato-biliary disorders: Abnormal liver function,...

Gravidanza

Teratogenic effects Acetazolamide, administered orally or parenterally, has been shown to be teratogenic (defects of the limbs) in mice, rats, hamsters, and rabbits. There are no adequate and well-controlled studies in pregnant women. Acetazolamide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Titolare dell'autorizzazione:

Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

Versione della scheda:

12 maggio 2026

Le sezioni qui sopra sono citate dalla scheda in lingua inglese, perché è quel documento a portare l'approvazione. Dove un'autorità europea pubblica le stesse informazioni in italiano, il link è tra le fonti. Non traduciamo da soli i testi regolatori: un errore di traduzione in una controindicazione sarebbe più pericoloso di una riga in un'altra lingua.

Questa sezione riporta le informazioni sul prodotto approvate. Il testo è condensato dalla sintesi dell'autorità stessa e il documento completo è linkato tra le fonti.